CompanyQTTBNasdaqWaltham, MA

Q32 Bio Inc.

Q32 Bio develops bempikibart, a fully human anti-IL-7Rα antibody targeting adaptive immune regulators for autoimmune and inflammatory diseases.

SEC EDGAR ClinicalTrials.gov q32bio.com

8-KSep 30Latest SEC filing

Sep 30Latest story

September 2026

Q32 Bio reports Part B data for bempikibart in alopecia areata at EADV 2026

Sep 30Clinical readoutQ32 Bio Inc.

August 2026

Q32 Bio posts positive bempikibart Phase 2a data, plans registration study for 2027

Aug 5Quarterly updateQ32 Bio Inc.

July 2026

Q32 Bio prices public offering, expects about $187.6 million in net proceeds

Jul 15PartnershipQ32 Bio Inc.

Q32 Bio prices $200 million stock offering, cites SIGNAL-AA Part B data

Jul 15FinancingQ32 Bio Inc.

Q32 Bio reports positive Phase 2a bempikibart results in alopecia areata

Jul 13Clinical readoutQ32 Bio Inc.